Validation and expansion of the American gastroenterological association clinical care pathway for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Veeral Ajmera(University of California San Diego), Rohit Loomba(University of California San Diego), Kaleb Tesfai(University of California San Diego), Ricki Bettencourt(University of California San Diego), Vanessa Cervantes(University of California San Diego), Egbert Madamba(University of California San Diego), Lisa Richards(University of California San Diego), Scarlett Lopez(University of California San Diego)
Cited by 2
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k